Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA196932, CA187119, CA215244)
Received: 14 July 2020
Accepted: 29 March 2021
First Online: 10 May 2021
: A.J.B. receives research funding from Bayer, Merck and Novartis; is a consultant to Earli and HelixNano; and is a cofounder of Signet Therapeutics. K.-K.W. is a founder and equity holder of G1 Therapeutics and has consulting/sponsored research agreements with MedImmune, Takeda, TargImmune, BMS, AstraZeneca, Janssen, Pfizer, Novartis, Merck, Ono and Array. The remaining authors declare no competing interests.